China Pharma Holdings Net Income

China Pharma Holdings (CPHI) currently reports a net income of $-5T as of March 2026. That compares with $-3.3T in the prior-year period — down 49.1% year over year. That is below the Healthcare sector average of $17B. Use the charts on this page to explore China Pharma Holdings's net income history and peer comparisons.

China Pharma Holdings's net income decreased from $-3.3T to $-5T — a 49.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China Pharma Holdings's net income of $-5T is lower than the Healthcare sector average of $17B. That is roughly 30035.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

China Pharma Holdings reported $-5T in net income as of March 2026. That compares with $-3.3T in the prior-year period — down 49.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-5T, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $17B. From there, open related valuation or income-statement pages for China Pharma Holdings, and consider following CPHI for alerts when major investors trade the stock.